ISRCTN65055502已完成2 期
A multi-centre randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on the progression of left ventricular mass and diastolic function in patients with structural heart disease
niversité catholique de Louvain (Belgium)0 个研究点目标入组 296 人开始时间: 2015年10月30日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 296
研究概览
简要总结
2018 Protocol article in https://pubmed.ncbi.nlm.nih.gov/29932311/ protocol (added 05/06/2020) 2023 Results article in https://doi.org/10.1001/jamacardio.2023.3003 (added 06/10/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age between 18 and 90 years
- •2. Arterial hypertension on stable therapy according to current guideline algorithms (including stable medication for at least four weeks before inclusion)
- •3. Morphological signs of structural cardiac remodelling by echocardiography, i.e. increased LV mass index (110 g/m2 or higher for female; 134 g/m2 or higher for male subjects (Devereux, Reichek 1977)) or end-diastolic wall thickness >13 mm in at least one wall segment
- •4. Patients may have atrial fibrillation (AF), but with well-regulated ventricular response, i.e. heart rate<100/min at inclusion (RACE II - (Groenveld et al. 2013, 2013))
- •5. Written informed consent
- •6. For subjects unable to read and/or write, oral informed consent observed by an independent witness is acceptable if the subject has fully understood oral information given by the Investigator. The witness should sign the consent form on behalf of the subject
排除标准
- •1. Unstable hypertension with systolic BP=160 mm Hg and/or diastolic BP=100 mm Hg (confirmed at three consecutive office measurements in sitting position); if so, the patient may be re-screened after optimization of anti-hypertensive treatment, which should be stabilized for at least four weeks before inclusion.
- •2. Documented ischemic cardiac disease:
- •2.1. current angina pectoris or
- •2.2. ischemia on stress test or
- •2.3. untreated coronary stenosis >50% or
- •2.4. history of acute myocardial infarction (AMI) or
- •2.5. coronary artery bypass graft (CABG, < than 3 months prior to screening) or
- •2.6. percutaneous transluminal coronary angioplasty (PTCA) less than 3 months prior to screening.
- •3. History of hospitalization for overt heart failure within last 12 months
- •4. Patients after heart transplantation
- •5. Genetic hypertrophic or dilated cardiomyopathy
- •6. Dysthyroidism.
- •7. Severe valvulopathy (less than 1 cm2 aortic valve area or major mitral valve insufficiency at Doppler echocardiography)
- •8. NYHA-class > II
- •9. BMI > 40 kg/m2
- •10. EF < 50%, regardless of symptoms
- •11. Known other cause (i.e. COPD) of respiratory dysfunction; patients under positive pressure (CPAP) treatment for sleep apnea syndrome may be included, provided they have been under regular treatment for at least one year before inclusion in the study
- •12. eGFR < 30 ml/min
- •13. Abnormal liver function tests (AST or ALT >2 X upper normal limit or GGT>3x upper normal limit)
- •14. Type I diabetes, complicated type II diabetes (i.e. with documented coronary macroangiopathy , cfr exclusion criterion 1 or documented other vascular complication)
- •15. Patients with anemia (male: Hb <130 g/l, female: Hb <120 g/l)
- •16. Patients with bladder outlet obstruction
- •17. Patients using antimuscarinic cholinergic drugs for treatment of OAB
- •18. Current use of digitalis, bupranolol, propranolol, nebivolol (known to interfere with ß3AR signalling)*
- •19. Patients continuously treated with Sildenafil or other PDE5 inhibitors
- •20. Current use of antifungal azole derivatives (fluconazole, itraconazole, miconazole, posaconazole, voriconazole) (known inhibitors of CYP3A4, the main metabolizer of mirabegron)
- •21. Current treatment with mirabegron or indication for future treatment with mirabegron due to other indications
- •22. Contraindication for MRI (e.g. pacemaker, defibrillator, ferromagnetic devices or severe claustrophobia)
- •23. Pregnant or nursing women
- •24. Participation in any other interventional trial
- •25. Fertile women (within two years of their last menstruation) without appropriate contraceptive measures (hormonal implant, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial (participants using a hormone-based method have to be informed of possible effects from the trial medication on contraception)
- •26. Contraindication to mirabegron (e.g. hypersensitivity) or any other components of the trial medication
- •* Note: patients are allowed
研究者
相似试验
已完成
不适用
Standard open radical cystectomy (ORC) versus robotically assisted radical cystectomy (RARC)Malignant neoplasm of bladderCancerBladder cancerISRCTN13680280niversity College London338
进行中（未招募）
不适用
Molecular point-of-care 'test and treat' for influenza (FluPOC)InfectionInfections and InfestationsISRCTN17197293niversity Hospital Southampton NHS Foundation Trust613
进行中（未招募）
2 期
A trial looking at the use of bronchodilator and steroid inhalers for preventing flare ups of bronchiectasisRespiratoryBronchiectasisISRCTN15988757ewcastle upon Tyne Hospitals NHS Foundation Trust600
已完成
不适用
Theophylline With Inhaled CorticoSteroid (ICS)Topic: Primary Care Research Network for England, RespiratorySubtopic: Not Assigned, Respiratory (all Subtopics)Disease: Respiratory, All DiseasesRespiratoryChronic obstructive pulmonary disease, unspecifiedISRCTN27066620niversity of Aberdeen (UK)1,578
已完成
不适用
Doxycycline And Rifampin for Alzheimer's DiseaseAlzheimer's diseaseNervous System DiseasesISRCTN15039674McMaster University (Canada)500